RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with
relapsed multiple myeloma.
OBJECTIVES: I. Determine the efficacy of bryostatin 1 administered as a 72-hour continuous
infusion in patients with relapsed multiple myeloma. II. Determine the qualitative and
quantitative toxic effects of bryostatin 1 in these patients. III. Determine the duration of
response and survival following bryostatin 1 in these patients.
OUTLINE: All patients receive bryostatin 1 by 72-hour continuous infusion every 2 weeks
until disease progression or 2 courses beyond complete remission. Response is assessed after
every 4 courses. Patients are followed for survival.
PROJECTED ACCRUAL: A total of 15-25 evaluable patients will be entered into this study over
DISEASE CHARACTERISTICS: Multiple myeloma of any stage that has failed 1 or 2 prior
regimens (chemotherapy, biologic therapy, or both, or bone marrow transplantation)
Evidence of disease progression required Ineligible for known treatment of higher
potential efficacy One of the following protein criteria required: Quantifiable
M-components of IgG, IgA, IgD, or IgE Urinary kappa or lambda light chain (Bence-Jones
protein) excretion Re-treatment on this protocol allowed if disease relapsed after a
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:
At least 12 weeks Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet
count greater than 50,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Transaminases less
than 2.5 times normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance
at least 60 mL/min Cardiovascular: No history of impaired cardiac status, e.g.: Severe
coronary artery disease Cardiomyopathy Congestive heart failure Arrhythmia Other: No known
AIDS or HIV infection No second malignancy within 5 years except: Adequately treated
nonmelanomatous skin cancer Carcinoma in situ of the cervix No pregnant or nursing women
Effective contraception required of fertile patients during and for 2 months after study
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See
Disease Characteristics At least 4 weeks since chemotherapy (8 weeks since mitomycin or
nitrosoureas) and recovered Endocrine therapy: No concurrent steroids Radiotherapy: At
least 4 weeks since radiotherapy and recovered Surgery: Not specified